Precede Biosciences Presents New Data at ESMO 2024 - GlobeNewswire
Precede Biosciences presented data at the 2024 ESMO Annual Meeting demonstrating their epigenomic liquid biopsy platform's ability to assess tumor PSMA expression from blood, aiding in patient identification for PSMA-targeting therapies.
Reference News
Precede Biosciences Presents New Data at ESMO 2024 - GlobeNewswire
Precede Biosciences presented data at the 2024 ESMO Annual Meeting demonstrating their epigenomic liquid biopsy platform's ability to assess tumor PSMA expression from blood, aiding in patient identification for PSMA-targeting therapies.